Colorectal adenocarcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- The most common type of colorectal carcinoma. It is characterized by the presence of malignant glandular epithelial cells invading through the muscularis mucosa into the submucosa. Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Colorectal adenocarcinoma
- Therapeutic area
- Oncology
- colorectal adenocarcinoma
- adenocarcinoma of large bowel
- adenocarcinoma of large intestine
- adenocarcinoma of the large bowel
- adenocarcinoma of the large intestine
- colorectal (colon or rectal) adenocarcinoma
- colorectal adenocarcinoma
- colorectum adenocarcinoma
- large bowel adenocarcinoma
- Severity
- Severe
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0005008
- Parent condition
- MONDO:0004970
Related records
Broader conditions (23)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Colorectal cancer
- Colorectal carcinoma
- Colorectal neoplasm
- Digestive system cancer
- Digestive system carcinoma
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Glandular cell neoplasm
- Human disease
- Intestinal cancer
- Intestinal disorder
- Intestinal neoplasm
Narrower conditions (24)
- Anal canal adenocarcinoma
- Anal canal Paget disease
- Anal gland adenocarcinoma
- Anal mucinous adenocarcinoma
- Anal Paget disease
- Anus adenocarcinoma
- Appendix adenocarcinoma
- Appendix mucinous cystadenocarcinoma
- Cecum adenocarcinoma
- Colon adenocarcinoma
- Colon medullary carcinoma
- Colon mucinous adenocarcinoma
- Colon signet ring cell adenocarcinoma
- Colorectal medullary carcinoma
- Colorectal serrated adenocarcinoma
- Colorectal signet ring cell carcinoma
- Mucinous adenocarcinoma of the appendix
- Perianal skin Paget disease
- Pseudomyxoma peritonei
- Rectal medullary carcinoma
Trials (151)
- 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
- A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
- A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
- A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
- A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
- A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer
- A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
- A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
- A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
- A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
- A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
Approved drugs (13)
- Aflibercept
- Bevacizumab
- Capecitabine
- Cetuximab
- Encorafenib
- Fruquintinib
- Ipilimumab
- Levoleucovorin calcium
- Nivolumab
- Panitumumab
- Regorafenib
- Tipiracil hydrochloride
- Trifluridine
Drugs in development (93)
- Aminolevulinic acid Phase 1
- Antineoplaston A10 Phase 2
- Ascorbic acid Phase 3
- Atorvastatin Phase 1
- Avelumab Phase 2
- Avutometinib Phase 2
- Bermekimab Phase 3
- Bintrafusp alfa Phase 2
- Brivanib Phase 2
- Cabozantinib Phase 2
- Cadonilimab Phase 2
- Camrelizumab Phase 2
- Cantuzumab ravtansine Phase 1
- Celecoxib Phase 3
- Cholecalciferol Phase 3
- Cisplatin Phase 3
- Clobetasol propionate Phase 2
- Dexamethasone Phase 3
- Doxycycline Phase 2
- Durvalumab Phase 2